

Practical Gynecology, 2nd Edition – Chapter 6 References

- *1. **Grimes DA, Creinin MD.** Induced abortion: an overview for internists. *Ann Intern Med.* 2004 Apr 20;140(8):620-6. *This excellent review of related evidence describes epidemiology and protocols in a way that is approachable and clinically relevant.*
2. **Weiss JL, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, Hankins GD, Berkowitz RL, Gross SJ, Dugoff L, Timor-Tritsch IE, D'Alton ME; FASTER Consortium.** Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. *Am J Obstet Gynecol.* 2004;190(3):745-50.
3. **Johns J, Jauniaux E.** Threatened miscarriage as a predictor of obstetric outcome. *Obstet Gynecol.* 2006;107(4):845-50.
- *4. Nanda K, Pelligia A, Grimes D, Lopez L, Nanda G. Expectant care versus surgical treatment for miscarriage. *Cochrane Database of Systematic Reviews* 2006(2).
5. **ACOG.** Early pregnancy loss: miscarriage and molar pregnancy. Patient pamphlet, 2002.
6. **McBride WZ.** Spontaneous abortion. *Am Fam Physician.* 1991;43:175-82.
7. **Herbst AL, Mishell DR Jr, Stenchever MA, Droegemueller W.** *Comprehensive Gynecology*, 2nd ed. St Louis: Mosby-Year Book; 1992:426-7.
- *8. **Speroff L, Glass RH, Kase NG.** *Clinical Gynecologic Endocrinology and Infertility*, 5th ed. Baltimore: Williams and Wilkins; 1994:842.
9. **Smith KE, Buyalos RP.** The profound impact of patient age on pregnancy outcome after early detection of fetal cardiac activity. *Fertil Steril.* 1996;65:35-40.
10. **Cunningham FG, MacDonald PC, Grant NF, et al.** *Williams Obstetrics*. Norwalk, CT: Appleton and Lange; 1993:666.
11. **Armstrong BG, McDonald AD, Sloan M, et al.** Cigarette, alcohol, and coffee consumption and spontaneous abortion. *Am J Public Health.* 1992;82:85-7.
12. **Temmerman M, Lopita MI, Sanghvi HC, et al.** The role of maternal syphilis, gonorrhea, and HIV-1 infections in spontaneous abortions. *Intl J STD AIDS.* 1992;3:418-22.
13. **Schenker MB, Gold EB, Beaumont JJ, et al.** Association of spontaneous abortion and other reproductive effects with work in the semiconductor industry. *Am J Ind Med.* 1995;28:639-59.
14. **Galindo A, Burguillo AG, Azriel S, Fuente Pde L.** Outcome of fetuses in women with pregestational diabetes mellitus. *J Perinat Med* 2006;34(4):323-31.

- *15. **Heffner LJ.** Advanced maternal age—how old is too old? *N Engl J Med.* 2004 Nov 4;351(19):1927-9.
16. **Ness RB, Grisso JA, Hirschinger N, Markovic N, Shaw LM, Day NL, Kline J.** Cocaine and tobacco use and the risk of spontaneous abortion. *N Engl J Med* 1999 Feb 4;340(5):333-9.
- *17. **Maconochie N, Doyle P, Prior S, Simmons R.** Risk factors for first trimester miscarriage—results from a UK-population-based case-control study. *BJOG.* 2007 Feb;114(2):170-86.
18. **Lindstrand A, Bergstrom S, Bugalho A, et al.** Prevalence of syphilis infection in Mozambican women with second trimester miscarriage and women attending antenatal care in second trimester. *Genitourin Med.* 1993;69:431-3.
- *19. **Gabbe S, Niebyl JR, Simpson JL.** *Obstetrics: Normal and Problem Pregnancies*, 2nd ed. New York: Churchill Livingstone; 1999:1140.
20. **Eberhart-Phillips JE, Frederick PD, Baron RC, Mascola L.** Measles in pregnancy: a descriptive study of 58 cases. *Obstet Gynecol.* 1993;82:797-801.
21. **Llahi-Camp JM, Rai R, Ison C, Regan L, Taylor-Robinson D.** Association of bacterial vaginosis with a history of second trimester miscarriage. *Hum Reprod.* 1996;11(7):1575-8.
22. **Horowitz S, Mazor M, Romero R, et al.** Infection of the amniotic cavity with *Ureaplasma urealyticum* in the midtrimester of pregnancy. *J Reprod Med.* 1995;40:375-9.
23. **Daugaard HO, Thomsen AC, Henriques U, Ostergaard A.** Group B streptococci in the lower urogenital tract and late abortions. *Am J Obstet Gynecol.* 1988;158:28-31.
24. **Andersen AM, Vastrup P, Wohlfahrt J, Andersen PK, Olsen J, Melbye M.** Fever in pregnancy and risk of fetal death: a cohort study. *Lancet.* 2002;Nov 16;360(9345):1552-6.
25. **Molo MW, Kelly M, Balos R, et al.** Incidence of fetal loss in infertility patients after detection of fetal heart activity with early transvaginal ultrasound. *J Reprod Med.* 1993; 38:804-6.
26. **Rempen A.** The incidence of abortions of viable pregnancies in the first trimester. *Zentralbl Gynakol.* 1993;115(6):249-57.
27. **Aral K, Gurkan Zorlu C, Gokmen O.** Plasma human chorionic gonadotropin levels after induced abortion. *Adv Contracept.* 1996;12(1):11-4.
- *28. **Harwood B, Meckstroth KR, Mishell DR, Jain JK.** Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. *Contraception.* 2001;63(5):255-6

29. **World Health Organization.** Safe Motherhood: Clinical Management of Abortion Complications—A Practical Guide. Geneva 1994.
30. **Sood M, Juneja Y, Goyal U.** Maternal mortality and morbidity associated with clandestine abortions. *J Indian Med Assoc.* 1995;93(2):77-9.
31. **Davis AR, Hendlish SK, Westhoff C, Frederick MM, Zhang J, Gilles JM, Barnhart K, Creinin MD.** Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial. *Am J Obstet Gynecol.* 2007;196(1):31.e1-7.
- *32. **Rizzi RG.** Incomplete Abortion, in *Misoprostol Use in Obstetrics and Gynecology*, ed Faúndes A, 2nd edition, chapter 5. 2007; FLASOG. *This informative chapter succinctly summarizes available evidence regarding misoprostol use for incomplete abortion. It includes information on indications and protocols for use as well as side effects and complications.*
33. **Shankar M, Economides DL, Sabin CA, Tan B, Kadir RA.** Outpatient medical management of missed miscarriage using misoprostol. *J Obstet Gynaecol.* 2007;Apr;27(3):283-6.
- *34. **Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM.** A comparison of medical management with misoprostol and surgical management for early pregnancy failure. *N Engl J Med.* 2005;353(8):761-69. *This large trial prospectively randomized 652 women experience early pregnancy failure (mostly missed with some incomplete and inevitable abortions) to either vaginal misoprostol 800 µg (with repeat on day 3 if expulsion had not yet occurred) or vacuum aspiration. The misoprostol and vacuum aspiration arms achieved 8% and 97% success, respectively, with no difference in complications.*
- *35. **Weeks A, Alia G, Blum J, Winikoff B, Edwaru P, Durocher J, Mirembe F.** A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. *Obstet Gynecol.* 2005;106:540-547. *This prospective trial randomized 317 women with incomplete first trimester abortion to treatment with either manual vacuum aspiration or misoprostol 600 µg orally. Treatment was successful in 91 of women treated with manual vacuum aspiration, and 96% of women treated with misoprostol. Women treated medically experienced fewer complications.*
- *36. **Bagratee JS, Khullar V, Regan L, Moodley J, Kagoro H.** A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. *Human Reproduction.* 2004;19(2):266-271.
37. **Finer L, Henshaw S.** Estimates of U.S. Abortion Incidence, 2001-2003. http://www.guttmacher.org/pubs/2006/08/03/ab_incidence.pdf, accessed on January 3, 2008.
- *37A. **Jones RK, Zolna MRS, Henshaw SK, Finer LB.** Abortion in the United States: Incidence and access to services, 2005. *Perspectives on Sexual and Reproductive Health.* 2008;40(1):6-16.

38. **National Center for Health Statistics Health.** United States, 2006 With Chartbook on Trends in the Health of Americans Hyattsville, MD: 2006. Table 16.

*39. **World Health Organization.** Safe abortion: technical and policy guidance for health systems. Geneva, 2003. *This book was written in response to the United Nations Millennium Summit in 2000, and describes evidence-based protocols for both individual practitioners delivering clinical care as well as health systems striving to deliver high quality services. More information is available on-line at http://who.int/reproductive-health/publications/safe_abortion/index.html.*

40. **World Health Organization.** Unsafe abortion: global and regional estimates of the incidence of unsafe abortion and associated mortality in 2000. 4th ed. Geneva: WHO; 2004.

*41. **Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA, Whitehead S, Atrash HK.** Risk factors for legal induced abortion-related mortality in the United States. *Obstet Gynecol.* 2004;103:729-37. *This important descriptive epidemiologic study summarizes mortality data obtained from the CDC for abortions performed in the U.S. Abortion-related mortality clearly decreased as safe abortion became legal and more accessible in the U.S.*

*42. **Goldberg AB, Dean G, Kang MS, Youssof S, Darney PD.** Manual versus electric vacuum aspiration for early first-trimester abortion: a controlled study of complication rates. *Obstet Gynecol.* 2004;103(1):101-7. *This retrospective cohort analysis reviewed charts for 1726 women undergoing manual or electric vacuum aspiration for abortions performed up to 10 weeks' gestation. No difference was found in complication rates; both techniques resulted in a reaspiration rate of approximately 2%. This study concluded that increased use of manual vacuum aspiration may increase abortion access.*

43. **Wiebe ER, Trouton K.** Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion. *Contraception* 2004;70(6):463-6.

*44. **Fiala C, Gemzel-Danielsson K.** Review of medical abortion using mifepristone in combination with a prostaglandin analogue. *Contraception.* 2006;74(1):66-86.

45. **Creinin MD, Vittinghoff E, Keder L, et al.** Methotrexate and misoprostol for early abortion: a multicenter trial. *Contraception.* 1996;53:321-7.

46. **Creinin MD, Vittinghoff E, Schaff E, et al.** Medical abortion with oral methotrexate and vaginal misoprostol. *Obstet Gynecol.* 1997;90:611-6.

47. **Shannon C, Wiebe E, Jacot F, Guilbert E, Dunn S, Sheldon WR, Winikoff B.** Regimens of misoprostol with mifepristone for early medical abortion: a randomized trial. *BJOG.* 2006;113(6):621-8.

*48. **Clark W, Panton T, Hann L, Gold M.** Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. *Contraception.* 2007;75(2):131-5.

49. **MifeprexTM (mifepristone) [package insert]**. Danco Laboratories LLC; 2000.
50. **Shannon CS, Winikoff B, Hausknecht R, Schaff E, Blumenthal PD, Oyer D, Sankey H, Wolff J, Goldberg R**. Multicenter trial of a simplified mifepristone medical abortion regimen. *Obstet Gynecol*. 2005;105(2):345-51
51. **Schaff EA, Fielding SL, Eisinger SH, et al**. Low dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. *Contraception*. 2000;61:41-6.
- *52. **Middleton T, Schaff E, Fielding SL, Cahill S, Shannon C, Westheimer E, Wilkinson T, Winikoff B**. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. *Contraception*. 2005;72(5): 328-32.
- *53. **Schaff EA, Fielding SL, Westhoff C, et al**. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortions: a randomized trial. *JAMA*. 2000;284:1948-53.
54. **Hamoda H, Ashok PW, Flett GM, Templeton A**. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. *BJOG*. 2005;112(8):1102-8.
- *55. **Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K**. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. *Eur J Obstet Gynecol Reprod Biol*. 2003;109(2):190-5.
56. **Spitz IM, Bardin CW, Benton L, Robbins A**. Early pregnancy termination with mifepristone and misoprostol in the United States. *N Engl J Med*. 1998;338(18):1241-7.
57. **Aubeny E, Peyron R, Turpin CL, et al**. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected]. *Int J Fertil Menopausal Stud* 1995;40 Suppl 2:85-91.
58. **Peyron R, Aubeny E, Targosz V, et al**. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. *N Engl J Med*. 1993;27;328(21):1509-13.
59. **Ashok PW, Penney GC, Flett GM, Templeton A**. An effective regimen for early medical abortion: A report of 2000 consecutive cases. *Hum Reprod*. 1998;13(10):2962-5.
- *60. **von Hertzen H, Honaken H, Piaggio G, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K, Gopalan S, Horga M, Jerve F, Mittal S, Nogu NT, Peregoudov A, Prasad RN, Pretnar-Darovec A, Shah RS, Song S, Tang OS, Wu SC**. WHO Research Group on Post-Ovulatory Methods for Fertility Regulation. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. *BJOG*. 2003;110(9):808-18.

- *61. **Aldrich T, Winikoff B.** Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. *BJOG*. 2007;114:555-562.
- *62. **Moreno-Ruiz NL, Borgatta L, Yanow S, Kapp N, Wiebe ER, Winikoff B.** Alternatives to mifepristone for early medical abortion. *Int J Gynaecol Obstet*. 2007;96(3):212-8.
63. **Goldberg AB, Drey EA, Whitaker AK, Kang MS, Meckstroth KR, Darney PD.** Misoprostol compared with laminaria before early second-trimester surgical abortion: a randomized trial. *Obstet Gynecol*. 2005;106(2):234-41.
64. **Patel A, Talmont E, Morfesis J, Pelta M, Gatter M, Momtaz MR, Piotrowski H, Cullins V.** Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. *Contraception*. 2006;73(4):420-30.
- *65. **Castleman LD, Oanh KT, Hyman AG, Thuy le T, Blumenthal PD.** Introduction of the dilation and evacuation procedure for second-trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol. *Contraception*. 2006;74(3):272-6.
66. **Ashok PW, Templeton A, Wagaarachchi PT, Flett GM.** Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. *Contraception*. 2004;69(1):51-8.
67. **Boyd EF, Holmstrom EG.** Ovulation following therapeutic abortion. *Am J Obstet Gynecol*. 1972;113(4):469-73.
68. **Grimes DA, Schulz KF, Cates WJ Jr.** Prevention of uterine perforation during curettage abortion. *JAMA*. 1984;251:2108-11.
- *69. **Hausknecht R.** Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. *Contraception*. 2003;67(6):463-5. *This informative paper reviews the first 18 months of experience using mifepristone in the U.S. Over 80,000 women used it during this time with very low rates of reported adverse events: 0.016% of women treated received a blood transfusion; 0.006% had an ectopic pregnancy; 0.013% were treated with antibiotics for a presumed infection.*
70. **Centers for Disease Control and Prevention.** Abortion surveillance—United States, 2003. *Surveillance Summaries*, Nov 26 MMWR. 2006;55(No. SS-11).
71. **Hoyert DL.** Maternal mortality and related concepts. *National Center for Health Statistics. Vital Health Stat* 3(33). 2007.